Pituitary dwarfism
Drug research and approvals for pituitary dwarfism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 20 studies of pituitary dwarfism are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 20
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Charactertizing Growth Hormone Deficiency in Traumatic Brain InjuryNCT07795736 · Not reported · University of Calgary · starts Jun 1, 2024
- GB06 Phase III Trial for Pediatric Growth Hormone DeficiencyNCT07553351 · Phase 3 · Kexing Biopharm Co., Ltd. · starts Jun 6, 2026
- Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone DeficiencyNCT07551804 · Phase 2 · Xiamen Amoytop Biotech Co., Ltd. · starts Jun 10, 2026
- REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)NCT07412782 · Not applicable · Meyer Children's Hospital IRCCS · starts Dec 4, 2025
- Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired…NCT07333521 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jan 13, 2026
- A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)NCT07264595 · Phase 1 / Phase 2 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Jan 18, 2026
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and…NCT07221851 · Phase 3 · Ascendis Pharma A/S · starts Dec 12, 2025
- A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)NCT07016802 · Phase 1 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Jun 9, 2025
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyNCT06948214 · Phase 3 · Lumos Pharma · starts May 20, 2026
Approved 5
- SomatropinGrowth hormone receptor agonist
- SomatrogonGrowth hormone receptor agonist
- SomapacitanGrowth hormone receptor agonist
- LonapegsomatropinGrowth hormone receptor agonist
- Arginine hydrochloride
Phase 3 5
- Albusomatropin
- Somavaratan
- ClonidineAdrenergic receptor alpha-2 agonist
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- MacimorelinGhrelin receptor agonist
Phase 2 2
How its trials ended
149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 43 whose ending is known, 56% met their primary endpoint, 0% missed it and 44% stopped early.
- Completed, result not reported7349%
- Met its primary endpoint2416%
- Ongoing2013%
- Status unknown139%
- Stopped: other or unclear96%
- Stopped: lack of efficacy53%
- Stopped: enrollment or feasibility32%
- Stopped: sponsor or business decision21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA